Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?

被引：1

作者：

Uronis, H. E. ^{[1
]}

Hurwitz, H. I. ^{[1
]}

机构：

[1] Duke Univ, Med Ctr,Duke S Clin, Dept Med, Div Med Oncol, Durham, NC 27710 USA

来源：

NATURE CLINICAL PRACTICE ONCOLOGY | 2007年 / 4卷 / 04期

关键词：

bevacizumab; colorectal cancer; 5-fluorouracil; irinotecan; leucovorin; FLUOROURACIL; LEUCOVORIN;

D O I：

10.1038/ncponc0748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：214 / 215

页数：2

共 6 条

[1]

[Anonymous], ANN ONCOL

[2] Investigating the potential of bevacizumab in other indications: Metastatic renal cell, non-small cell lung, pancreatic and breast cancer [J].

de Gramont, A ;

Van Cutsem, E .

ONCOLOGY, 2005, 69 :46-56

[3]

Giantonio BJ, 2005, J CLIN ONCOL, V23, p1S

[4] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[5] Molecular regulation of vessel maturation [J].

Jain, RK .

NATURE MEDICINE, 2003, 9 (06) :685-693

[6] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

← 1 →